In experiments on a large group of subjects, it was announced that the coronavirus vaccine developed by Pfizer and BioNTech was “more than 90 percent effective” against Covid-19 virus. Pfizer and BioNTech announced the development in the words “a big day for science and humanity”.
The vaccine candidate in question was tested on 43,500 people in 6 countries. No serious safety concerns arose in the experiment.
It is reported that vaccine producing companies plan to apply for emergency use approval at the end of this month.
The vaccine will be administered in two doses, three weeks apart. Pfizer plans to launch 50 million doses of vaccine by the end of the year and 1.3 billion doses by the end of 2021.
Pfizer CEO Albert Bourla said he wanted to be among the first vaccines to allay public concerns about the vaccine’s safety, but added that ethical barriers could arise.
Speaking to CNBC, Bourla said, “If we have a limited dose of vaccine, I am not sure that people will approve of people of my age and capacity to be put into the first vaccine group. So I would like to respect that.”
Pfizer shares soared in pre-transactions before the US market opened, after the vaccine’s third-stage trials were announced successful. Later, it gained 17 percent value.
Uğur Şahin and Özlem Türeci, the founders of BioNTech
Biontech German company’s founders, a family of children who have migrated from Turkey to Germany Türeci craving and also the company’s CEO Ugur Sahin.
Uğur Şahin said that their results were a “turning point”.
Christian Odandahl, chief economist at the European Reform Center, tweeted, “Germany has long struggled with the issue of how open it should be about immigration, and the post-war” guest workers “program has always been questioned. Uğur Şahin’s father was one of these guest workers who came to work at the Ford factory in Cologne. “Now his son can be the person who put an end to the pandemic that surrounded the world.”
When can it start?
How quickly the vaccine manufacturer companies will respond to their application for emergency use approval at the end of this month will determine when the use of the vaccine will begin.
All over the world, vaccination is seen as the most effective way to end the pandemic measures that limit people’s lives, along with more advanced treatments.
There are currently more than 10 vaccine candidates in different parts of the world, whose final experiments known as “stage three” are underway. But Pfizer and BioNTech were the first to reach the conclusion.
A purely experimental approach was taken. Part of the partial genetic sequence of the virus is injected into the body to train the immune system against the virus.
In previous trials, it was revealed that the vaccine caused the production of cells that are part of the immune system called antibodies and T cells in the body. Two doses of the vaccine will need to be given three weeks apart.
Essays USA, Germany, Brazil, Argentina, South Africa and Turkey continued and revealed a second dose of vaccine than 7 days after it provides 90 percent protection against coronaviruses.
Britain had ordered 10 million doses before the trials were completed by the end of the year, and already 30 million doses for next year. However, some logistical problems may occur due to the necessity of keeping the vaccine at minus 80 degrees Celsius.